Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Follow up complete |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase I clinical trial to evaluate the safety and immunogenicity of Polyvalent env (A, B, C, E)/gag (C) DNA and gp 120 (A,B,C,E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as either a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1 uninfected adult participants
Description
HVTN 124 is a Phase I clinical trial to evaluate the safety and immunogenicity of env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein/GLA-SE HIV-1 vaccines (PDPHV-201401).
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.